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In Brief
Butyrophilin (BTN) and butyrophilin-like
(BTNL) molecules powerfully influence
selection and activation of specific gd
lymphocyte subsets, but whether they
directly bind the gd TCR has remained
contentious. Willcox et al. show that
BTNL3 directly binds to human Vg4+
TCRs via a superantigen-like binding
mode that is focused on germline-
encoded TCR regions.nc.
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Butyrophilin (BTN) and butyrophilin-like (BTNL/Btnl)
heteromers are major regulators of human and
mouse gd T cell subsets, but considerable conten-
tion surrounds whether they represent direct gd
T cell receptor (TCR) ligands. We demonstrate that
the BTNL3 IgV domain binds directly and specifically
to a human Vg4+ TCR, ‘‘LES’’ with an affinity (15–
25 mM) comparable to many ab TCR-peptide major
histocompatibility complex interactions. Mutations
in germline-encoded Vg4 CDR2 and HV4 loops, but
not in somatically recombined CDR3 loops, drasti-
cally diminished binding and T cell responsiveness
to BTNL3-BTNL8-expressing cells. Conversely,
CDR3g and CDR3d loopsmediated LES TCR binding
to endothelial protein C receptor, a clonally restricted
autoantigen, with minimal CDR1, CDR2, or HV4 con-
tributions. Thus, the gd TCR can employ two discrete
binding modalities: a non-clonotypic, superantigen-
like interaction mediating subset-specific regulation
by BTNL/BTNmolecules and CDR3-dependent, anti-
body-like interactions mediating adaptive gd T cell
biology. How these findings might broadly apply to
gd T cell regulation is also examined.
INTRODUCTION
gd T cells seemingly make both innate-like and adaptive contri-
butions to immunity, with increasingly appreciated relevance to
clinical scenarios such as cancer surveillance. Prototypic
innate-like gd T cell subtypes include mouse dendritic epidermal
T cells (DETCs), which are skin-restricted, feature a canonical
T cell receptor (TCR) repertoire (Asarnow et al., 1988), and
mediate responses to dysregulated target cells in the absenceImmunity 51, 813–825, Nove
This is an open access article undof foreign adjuvants or antigens (Strid et al., 2008). Indeed,
DETC-deficient mice show increased susceptibility to skin carci-
nogenesis (Girardi et al., 2001). In humans, a limited TCR reper-
toire is likewise expressed by a major subset of Vg9Vd2 T cells
(Delfau et al., 1992), which are preferentially enriched in periph-
eral blood, display an effector phenotype (Parker et al., 1990),
and show potent cytotoxicity and cytokine production. Given
that they respond en masse to microbial phosphoantigens
(P-Ags) (Morita et al., 2007), the Vg9Vd2 subset likely provides
an early line of defense against certain microbial infections,
such as those involving eubacterial and mycobacterial species
that produce the highly potent P-Ag (E)-4-hydroxy-3-methyl-
but-2-enyl pyrophosphate (HMBPP). Conversely, adaptive
paradigms seem most able to explain conspicuous clonal ex-
pansions and effector differentiation of subsets of human Vd2neg
T cells and Vg9negVd2 T cells, including after exposure to viral
infection (Davey et al., 2017, 2018b; Ravens et al., 2017).
Few direct ligands of the gd TCRs underpinning innate-like or
adaptive responses are known. Adaptive processes highlight
powerful clonotypic focusing even within specific V region
subsets (e.g., Vd1 T cells, Vd1negVd2neg T cells, and Vg9negVd2
T cells), strongly suggesting that somatically recombined
CDR3 regions are involved (Davey et al., 2018a). Moreover, a
diverse range of ligands has been proposed for such popula-
tions, including those few supported by evidence of direct
TCR-ligand interaction, many of which favor roles for CDR3
residues (Willcox and Willcox, 2019).
At the same time, molecules closely related to the B7 family of
lymphocyte co-regulators (which include CD80, ICOS-L, and
PDL1) have emerged as critical players in gd T cell selection,
activation, and possibly tissue-associated functions (Abeler-
Do¨rner et al., 2012). The first of these to be identified was Skint1,
a hitherto uncharacterized BTNL molecule crucial for thymic se-
lection of Vg5+ DETC and expressed by keratinocytes (Boyden
et al., 2008). Subsequently, expression of the human BTN3A1
molecule on target cells was established as critical for P-Ag-
mediated activation of human peripheral blood Vg9Vd2+ T cells
(Harly et al., 2012; Vavassori et al., 2013). More recently, mousember 19, 2019 ª 2019 The Authors. Published by Elsevier Inc. 813
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Btnl1 emerged as critical for the extrathymic selection of the
signature Vg7+ intestinal intraepithelial lymphocyte (IEL) popula-
tion (Di Marco Barros et al., 2016). Btnl1 and Btnl6 molecules are
both expressed by differentiated enterocytes (Di Marco Barros
et al., 2016), wherein they form a co-complex (Lebrero-Ferna´n-
dez et al., 2016a; Vantourout et al., 2018) that can specifically
regulate mature Vg7+ IEL in vitro. Likewise, human BTNL3 and
BTNL8, which are both enriched in expression in gut epithelium
(Di Marco Barros et al., 2016; Lebrero-Ferna´ndez et al., 2016b),
aremajor regulators of signature human intestinal Vg4+ T cells (Di
Marco Barros et al., 2016; Melandri et al., 2018) and are capable
of inducing TCR downregulation specifically in this subset. The
potential pathophysiologic significance of the Vg4+ T cell subset
was highlighted recently by a report that disruption of the Vg4+
-BTNL3.8 axis is pathognomonic for celiac disease (Mayassi
et al., 2019). More generally, TCR gd IELs have been increasingly
implicated in the regulation of tissuemaintenance, including pro-
tection from infection, inflammation, and internal dysregulation
(Edelblum et al., 2015; He et al., 2019; Hoytema van Konijnen-
burg et al., 2017). Thus, deficiencies in signature, tissue-resident
gd T cell compartments have been causally linked to cancer and
tissue inflammation (Girardi et al., 2002; Roberts et al., 1996;
Strid et al., 2008).
Soon after their discovery, when gd T cells were first found to
express a limited number of V regions, the existence of a range of
host-encoded ligands that might mediate subset-specific gd
T cell selection and/or activation was hypothesized (Janeway
et al., 1988). Clearly, the observations outlined earlier highlight
BTN and BTNL molecules as strong candidates for being direct,
subset-specific gd TCR ligands. Nevertheless, the only study re-
porting direct binding of a TCR (Vg9Vd2) to a BTN or BTNLmole-
cule (BTN3A1) (Vavassori et al., 2013) has been strongly
disputed (Sandstrom et al., 2014), with its claim of P-Ag presen-
tation by the BTN3A1 V domain being ascribed to electron den-
sity arising from crystallization components (Sandstrom et al.,
2014). Indeed, other data demonstrate that BTN3A1 can directly
bind P-Ag in its C-terminal B30.2 domain (Hsiao et al., 2014;
Salim et al., 2017; Sandstrom et al., 2014). Altogether, compel-
ling evidence that any BTN, BTNL, or Btnl molecule acts as a
direct ligand for the gd TCR is lacking, leaving uncertainty about
how these molecules may achieve their profound biological ef-
fects. Indeed, the possibility has remained that BTN and BTNL
molecules may act indirectly, for example, as chaperones or in-
ducers for direct TCR ligands that are as yet unidentified.
Here we provide unequivocal evidence for direct binding of a
gd TCR to a BTNL protein.We show that a human Vg4 TCR binds
the BTNL3 IgV domain via germline-encoded regions, somewhat
analogous to superantigen binding to an ab TCR. In contrast,
binding of a clonally restricted ligand to the same Vg4 TCR
was critically influenced by the CDR3 regions of the gd TCR,
consistent with its adaptive biology. Thus, we highlight two
distinct and complementary modalities for ligand interaction:
one involving a BTNL molecule in Vg region-specific regulation
of tissue-restricted gd T cell subsets and the other involving
highly specific, clonally restricted ligand recognition, underpin-
ning adaptive gd T cell responses. Moreover, the two binding
modes may extend to BTN3A1-mediated regulation of the hu-
man blood Vg9Vd2 subset by P-Ags, suggesting broad signifi-
cance of the BTNL modality that we outline.814 Immunity 51, 813–825, November 19, 2019RESULTS
The BTNL3 IgV Domain Directly and Specifically Binds
Vg4 TCRs
Previously, we demonstrated that exposure of Jurkat cells
transduced with Vg4+ gd TCRs to 293T cells expressing
BTNL3.8 heterodimers (293T.L3L8) led to CD69 upregulation
and TCR downregulation, consistent with TCR triggering (Melan-
dri et al., 2018). Moreover, soluble Vg4 TCRs were found to
specifically stain the surface of 293T.L3L8 target cells, but not
control cells transduced with empty vector (293T.EV), suggest-
ing that BTNL3.8 heterodimers either were Vg4 TCR ligands or
induced the display of as-yet-unidentified Vg4 TCR ligands.
Consistent with either possibility, mutagenesis of the BTNL3.8
heterodimer showed that Vg4-mediated TCR triggering de-
pended on the BTNL3 IgV domain.
To address the hypothesis that BTNL heterodimers directly
bound the TCR, we generated recombinant BTNL3 and BTNL8
IgV domains and tested interaction with a range of soluble gd
TCRs (Willcox et al., 2012) using surface plasmon resonance
(SPR). We overexpressed both BTNL IgV domains separately
in E. coli and then renatured them by dilution refolding, with
yields broadly similar to those of other B7-like IgV domains,
such as Skint1 (Salim et al., 2016) (STAR Methods). Of note,
BTNL3 IgV was highly susceptible to oxidation when solubilized
in denaturant, and its correct refolding depended on full reduc-
tion before refolding and choice of oxido-reduction couple
during renaturation. Refolding was also impaired by some
C-terminal tag sequences, although not by a 63His tag.
Injection of BTNL3 over immobilized Vg4 TCR resulted in
substantially greater signals than over immobilized Vg2 or
Vg3 TCRs, indicating Vg4-specific TCR binding (Figure 1A). In
contrast, signals resulting from injection of BTNL8 IgV over sur-
faces with immobilized Vg2, Vg3, and Vg4 TCRs matched
those over control surfaces, indicating that in contrast to
BTNL3 IgV, BTNL8 IgV did not directly bind the Vg4 TCR (Fig-
ure 1B). This was consistent with genetic data implicating
BTNL3 more than BTNL8 in promoting Vg4 TCR triggering
(Melandri et al., 2018). Equilibrium binding measurements (Fig-
ure S1A) indicated the affinity (Kd) of BTNL3 IgV for a Vg4 TCR,
LES, was 15–25 mM (average 20.7 ± 4.8 mM, n = 15) at 25C
(Figure 1C; Figure S1A). Isothermal titration calorimetry (ITC)
measurements confirmed Vg4 TCR specifically bound to
BTNL3 IgV, with a broadly similar affinity (3.5 mM at 20C),
and indicated the interaction was enthalpically driven
(DH = 8.1 kcal.mol1 at 20C) and marginally entropically un-
favorable (TDS = 0.77 kcal.mol1 at 20C) (Figures 1D
and 1E). In contrast, no binding was observed with a Vg2+ or
Vg3+ TCR (Figure 1E; Figures S1B and S1C).
Consistent with our finding that BTNL3 IgV, but not BTNL8
IgV, directly bound Vg4 TCRs, soluble Vg4 TCR binding to
293T cells transducedwith FLAG (N-terminal)-BTNL3 and hem-
agglutinin (HA) (N-terminal)-BTNL8 heterodimer constructs
was abrogated by anti-FLAG antibody, presumably because
of steric hindrance, but was only marginally affected by anti-
HA antibody (Figure 1F; Figure S1D). Anti-FLAG antibody, but
not anti-HA antibody, also inhibited activation of JRT3
Vg4Vd1 TCR transductants by 293T cells transduced with
FLAG-BTNL3.HA-BTNL8 (Figures S1E–S1G).
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Figure 1. Human BTNL3 IgV Binds Specifically to Vg4 TCRs
(A and B) SPR analysis of BTNL3 IgV (A; 18.2 mM) or BTNL8 IgV (B; 17.7 mM) injected (small horizontal bar) over biotinylated Vg4 TCR (1,805 RU), Vg3 TCR
(1,981 RU), or Vg2 TCR (1,872 RU) or streptavidin alone. Responses presented as resonance units (RUs). Data are representative of 15 experiments (A) or two
experiments (B).
(C) Equilibrium affinity analysis of the binding of BTNL3 IgV to Vg4 TCR (Kd = 22.1 mM); inset, Scatchard plot of the same data (Kd = 20.9 mM).
(D) ITC analysis of the BTNL3 IgV domain interaction with Vg4 TCR (Kd = 3.5 mM).
(E) ITC analysis indicates no interaction of the BTNL3 IgV domain with control Vg2+ or Vg3+ TCRs.
(F) Quantitation of effects of anti-FLAG and anti-HA antibodies on the staining of 293T cells expressing FLAG-BTNL3 and HA-BTNL8 with soluble Vg4+ TCR and
anti-His monoclonal antibody (mAb). Data are from three independent experiments (mean ± SD).
See also Figure S1.In addition, analogous results were obtained when Jurkat 76
(J76) cells expressing a mouse Vg7 TCR were stimulated with
MODE-K cells transduced with FLAG (N-terminal)-Btnl1 and
HA (N-terminal)-Btnl6 constructs, in which case the anti-HA anti-
body more potently abrogated J76 activation (Figures 2A and
2B; Figure S2A). This was consistent with evidence that the
responsiveness of Vg7+ T cells to Btnl1.6 was more potently
abrogated by mutations in the V region of Btnl6 compared with
Btnl1, suggestive of Btnl6 being a direct ligand for Vg7 (Melandri
et al., 2018). Indeed, soluble Vg7 TCR multimers specifically
stained cells expressing Btnl1.6 (293T.l1l6) (Figure 2C; Fig-
ure S2B) in a dose-dependent manner (Figure 2D; Figure S2C),
consistent with direct TCR-Btnl1.6 interactions.
Although our current and previous data suggested that multi-
ple Vd chains are compatible with Vg4-mediated recognition of
BTNL3.8, we could not exclude an effect of TCRd. Compounding
this, a recent study suggested that a certain Vg4 TCR was not
able to mediate BTNL3.8-driven responses in a cellular assay
and suggested that particularly long Vd1 CDR3 sequences might
explain this observation (Mayassi et al., 2019). To address this
more fully, we investigated Jurkat cells transduced with Vg4
TCRs—either hu12-g containing the H-J1 motif identified in
active celiac disease IELs (Mayassi et al., 2019) or hu20-g, aVg4 chain lacking the H-J1 motif (non-H-J1)—bearing a diverse
range of Vd1 chains (Melandri et al., 2018) (CDR3 ranged from 12
to 24 amino acids in length) for their capacity to upregulate CD69
and downregulate both TCR and CD3 in response to BTNL3.8-
expressing cells. Conspicuously, all combinations resulted in
similar degrees of gd TCR andCD3 downregulation (Figure S2D).
In addition, all constructs induced CD69 upregulation, although
modest differences between different TCRs were observed, as
we previously observed to be the case for TCR responses to
anti-CD3 antibodies, as well as to BTNL- or Btnl-expressing cells
(Melandri et al., 2018). These results establish that diverse Vd1
CDR3 regions are permissive for Vg4-mediated TCR triggering
in response to recognition of BTNL3.8 on target cells.
Germline-Encoded Regions of Vg4 Dominate BTNL3
Interaction
We then assessed which regions of the Vg4 TCR chain were
involved in directly engaging BTNL3. First, we generated Vg4
TCRs with charge reversal mutations in each of the three
CDRg and CDRd loops (Figure 3A). Second, based on amino
acid sequence comparisons of Vg4 with Vg2 (which does
not bind BTNL3), we generated Vg4 TCRs incorporating muta-
tions in the HV4g loop, which we previously implicated inImmunity 51, 813–825, November 19, 2019 815
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Figure 2. Mouse Vg7 TCR-Dependent Recognition of Btnl1.6
(A and B) Flow cytometry analysis of TCR downregulation (A) and CD69 upregulation (B) by Jurkat 76 cells transduced with mo5 Vg7Vd2-2 TCR and co-cultured
for 5 h with MODE-K.FLAG-l1.HA-l6 cells in the presence of the indicated concentrations of antibodies (x axis). Results were normalized to those obtained by
co-culture with transduced MODE-K.EV cells. Data are representative of three independent experiments (mean ± SD of n = 3 co-cultures).
(C) Specific staining of anti-His antibody alone (top row), soluble Vg7+ TCR and anti-His mAb (middle row), or Vg4+ TCR and anti-His mAb (bottom row) to 293T
cells expressing Btnl1.6, BTNL3.8, or control 293T.EV.
(D) Flow cytometry analysis of the staining of Btnl1.6-expressing 293T cells with increasing concentrations of soluble Vg7+ TCR and anti-His mAb.
See also Figure S2.BTNL3-mediated triggering of Vg4+ T cells (Melandri et al.,
2018). We chose the LES Vg4Vd5 TCR as a model clonotype
for these experiments, allowing comparison of the BTNL3 bind-
ing mode with that of endothelial protein C receptor (EPCR),
which we previously identified as a unique ligand for the LES
TCR (Willcox et al., 2012). BTNL3 binding affinity was substan-
tially decreased by mutation of CDR2g (Figure 3B; Figure S3A).
Binding was even more strongly affected by substitution of
Vg2 residues Y/A into the Vg4 HV4 loop (Figure 3B; Figure S3B),
whereas substitution of N/L residues resulted in only marginally
reduced affinity (Figure 3B). Consistent with this, LES TCR incor-
porating Vg2 residues Y/A in the Vg4 HV4 loop showed drasti-
cally reduced binding to BTNL3 by ITC (Figures S3C and S3D).
Finally, compared with changes in the CDR2g and HV4g loops,816 Immunity 51, 813–825, November 19, 2019mutations in CDR1g, CDR3g, CDR1d, CDR2d, and CDR3d had
either negligible or only modest effects on the interaction (Fig-
ure 3B). All soluble TCR (sTCR) mutants were folded correctly,
as determined by pan-gd TCR antibody binding (Figure S3E).
Based on these results, we hypothesized that the BTNL3-Vg4
interaction was heavily focused on the CDR2 and HV4 loop re-
gions of Vg4. To test this, we generated chimeric constructs (Fig-
ure 3A) in which the CDR2 and/or HV4 loop regions of human
Vg4 replaced the counterpart regions of Vg3 that are relatively
divergent from Vg4, differing overall by 24 amino acids, and
then tested the ability of Jurkat cells transduced with those
TCRs to upregulate CD69 and downregulate TCR in response
to BTNL3.8-expressing cells. In support of our hypothesis, trans-
ductants expressing a chimeric Vg3 construct that incorporated
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Figure 3. BTNL3 Binding to Vg4 Involves Germline-Encoded Regions, whereas Antigen-Specific Binding Requires CDR3g and CDR3d
Regions
(A) Amino acid sequence of human Vg4 and Vd5 from the LES clone, showing mutations tested in CDR1, CDR2, HV4, and CDR3 in red below (top).
(Middle) Amino acid sequence of human Vg4 from the hu17 TCR aligned to human Vg3 and the indicated Vg3/hu17 Vg4 hybrids transduced in JRT3. Red
font indicates divergence from WT Vg4. (Bottom) Alignment of the amino acid sequences of human Vg4 with mouse Vg7 and the CDR2 and HV4 chimeras
generated in the mo5 Vg7Vd2-2 TCR. Red font indicates amino acids from human Vg4 inserted in mouse Vg7 to generate the indicated chimeras,
expressed in Jurkat 76.
(B) Binding affinity of BTNL3 to indicated Vg4 and Vd5 mutants (mutant Kd) relative to WT LES TCR affinity (WT Kd) measured in the same experiment.
The averages of n = 4–5 experiments per Vg4 mutant and 1–2 experiments per Vd5 mutant are shown.
(legend continued on next page)
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Vg4 HV4 and CDR2 loops displayed degrees of CD69 upregula-
tion and TCR downmodulation comparable to those of WT Vg4
TCR transductants, whereas replacement of the HV4
loop alone conferred only partial recovery of reactivity upon
BTNL3.8 (Figure 3C; Figure S3F).
In parallel, we generated constructs of a mouse Btnl1.6-reac-
tive Vg7 TCR in which the CDR2 and HV4 loops were replaced
with their counterparts from human BTNL3.8-reactive Vg4 (Fig-
ure 3A) and thereupon assessed the responsiveness of Jurkat
transductants to mouse Btnl1.6 and human BTNL3.8, respec-
tively. Introduction of either HV4 or a combination of HV4 and
CDR2 sequences from human Vg4 into the mouse Vg7
sequence abolished murine Btnl1.6-mediated TCR downmo-
dulation and CD69 upregulation yet concomitantly conferred
reactivity to the human BTNL3.8 heterodimer (Figures 3D and
3E; Figure S3G). For TCR downmodulation, replacement of
HV4 and CDR2 conferred 90% of the BTNL3.8-induced
TCR downmodulation observed with WT Vg4 TCR transduc-
tants, while HV4 replacement alone conferred a partial
response. Of note, both the HV4 and the HV4 and CDR2
replacement constructs induced similar (>3-fold) increases in
CD69 expression over control in response to BTNL3.8-ex-
pressing target cells. Altogether, these results confirm that
reactivity to human BTNL3.8 is encoded substantially within
the germline-encoded HV4 and CDR2 regions of human Vg4
and that those regions alone were sufficient to convert a heter-
ologous mouse TCR into one with almost full reactivity toward
human BTNL3.8.
As a comparison for the BTNL3-TCR interaction, we tested
how mutations in the CDR loops of the LES TCR (Figure 3A)
affected EPCR binding. Mutation of LES CDR3g or CDR3d,
which minimally affected BTNL3 binding, eliminated LES bind-
ing to EPCR (Figure 3F; Figures S3H and S3I), consistent with
the pronounced and highly focused expansion of the LES clo-
notype observed following cytomegalovirus (CMV) infection
(Lafarge et al., 2005). By contrast, mutation of other CDR
loops in the Vg4 or Vd5 chains or of the HV4 region of Vg4
only modestly affected LES binding to EPCR (Figure 3F).
Thus, BTNL3 and EPCR bound Vg4 via fundamentally distinct
binding modes, raising the question of whether they could
bind the LES TCR simultaneously. Arguing against this, how-
ever, co-incubation of the LES TCR with BTNL3 IgV decreased
its EPCR binding in a concentration-dependent manner (to
<40%). This inhibition was specific, as judged by the failure
of co-incubation with BTNL8 IgV to affect EPCR binding
(Figure 3G).(C) Flow cytometry analysis of TCRdownregulation (x axis) plotted against that of C
TCR or the indicated Vg3 or Vg4 TCR hybrids and co-cultured for 4 h with 293T.L3
cells. Data are representative of two independent experiments (mean ± SD of n
(D and E) Flow cytometry analysis of TCR downregulation (D) and CD69 upregu
moVg7/huVg4 hybrid TCRs after co-culture with 293T.l1l6 or 293T.L3L8 cells. R
Data are representative of three independent experiments (mean ± SD of n = 3 c
(F) Binding affinity of EPCR to Vg4 and Vd5 mutants (mutant Kd) relative to WT LES
experiments.
(G) EPCR (3,012 RU) or control protein (2,586 RU) were immobilized on the sensor
increasing specific competitor (BTNL3 IgV) or non-specific competitor (BTNL8 IgV
observed in the absence of competitor.
See also Figure S3.
818 Immunity 51, 813–825, November 19, 2019Vg4 TCR Interaction Involves the CFG Face of the BTNL3
IgV Domain
To assess the regions of the BTNL3 IgV domain involved in
binding, we used SPR to test the interaction with Vg4 TCR of
four BTNL3 IgV domain mutants that incorporated changes in
the C0, C00 F, and G b strands of the BTNL3 IgV domain (CFG
face), as was recently considered (Melandri et al., 2018) (Fig-
ure 4A). Upon injection, the BTNL3GQFSS, BTNL3RI, and
BTNL3YQKAI mutants each exhibited minimal specific binding
to Vg4 TCR, with a substantially reduced affinity relative to
WT BTNL3 IgV, whereas the BTNL3KDQPFM mutant clearly re-
tained Vg4 binding (Figures 4B–4E; Figures S4A–S4D). More-
over, relative to WT BTNL3, the BTNL3RI mutant showed
reduced binding affinity to Vg4 TCR in ITC (Kd = 50 versus
3.5 mM for WT BTNL3) (Figures S4E and S4F). All BTNL3 mu-
tants bound polyclonal anti-BTNL3 antibody (Figures S4G
and S4H), suggesting that mutations in the CFG face did not
inhibit expression or refolding of BTNL3 IgV. In parallel, we ex-
pressed the corresponding mutations as BTNL3.8 hetero-
dimers in 293T cells and tested sTCR staining at the cell sur-
face. Consistent with the SPR results, cells expressing
BTNL3GQFSS.8, BTNL3RI.8, and BTNL3YQKAI.8 were not bound
by sTCR, whereas the BTNL3KDQPFM.L8 mutant retained TCR
staining, albeit reduced compared with WT BTNL3.8 (Fig-
ure 4F). Altogether, these experiments clearly implicate resi-
dues in the CFG face of BTNL3 in direct binding to the Vg4
TCR chain. In addition, Vg7 sTCR multimer staining to cells ex-
pressing Btnl1.6 was abolished by mutations of the counterpart
positions of Btnl6 IgV (Melandri et al., 2018) (Figure S4I). Thus, a
comparable mode of interaction is seemingly conserved from
mouse through to human.
Although we did not directly address the role of the IgC do-
mains of BTNL3 or BTNL8 in Vg4 TCR recognition, homology
modeling of the heterodimer based on the BTN3A1 homodimer
(PDB: 4F80) confirmed a strong potential for BTNL3 IgC-
BTNL8 IgC interchain heterodimer interactions (Figure S4J).
Conversely, the formation of BTNL3.8 heterodimers analogous
to non-symmetrical head-to-tail heterodimer interfaces
observed in the crystal structure of BTN3A1, BTN3A2, and
BTN3A3 (PDB: 4F80, 4F8Q, 4F8T) seems unlikely given compar-
isons of equivalent amino acids in BTNL3 IgV andBTNL8 IgC and
in BTNL3 IgC and BTNL8 IgV (Figure S4K). These analyses sug-
gest the BTNL3.8 heterodimer likely adopts a V-shaped dimer
configuration similar to that observed in the BTN3A1 crystal lat-
tice (Palakodeti et al., 2012), with the V region of one chain,
BTNL3, available for direct binding to the CDR2-HV4 face of Vg4.D69 upregulation (y axis) on JRT3 cells transducedwithwild-type (WT) Vg4Vd1
L8 cells. Results were normalized to those obtained by co-culture with 293T.EV
= 3 co-cultures).
lation (E) on J76 cells transduced with mo5 (Vg7Vd2-2) TCR or the indicated
esults were normalized to those obtained by co-culture with 293T.EV cells.
o-cultures).
TCR affinity (WT Kd) measured in the same experiment, representative of 2–3
chip. WT LES TCR was injected over the surface at 12.5 mM in the presence of
). Binding responses weremeasured and are shown as a percentage of binding
0.1 1 10 100 
 1 
10 
20 
30 
Concentration (μg/ml)
So
lu
bl
e 
Vγ
4V
δ1
 b
in
di
ng
(g
M
FI
 fo
ld
 re
la
tiv
e 
to
 c
trl
)
F
BTNL3 IgV WT
BTNL3GQFSS IgV
BTNL3KDQPFM IgV
BTNL3RI IgV
BTNL3YQKAI IgV
BTNL3 IgV  QWQVTGPGKFVQALVGEDAVFSCSLFPETSAEAMEVRFFR 
BTNL8 IgV QWQVFGPDKPVQALVGEDAAFSCFLSPKTNAEAMEVRFFR 
**** **.* *********.*** * *:*.**********
BTNL3 IgV NQFHAVVHLYRDGEDWESKQMPQYRGRTEFVKDSIAGGRV
BTNL8 IgV GQFSSVVHLYRDGKDQPFMQMPQYQGRTKLVKDSIAEGRI
.** :********:*    *****:***::****** **:
BTNL3 IgV SLRLKNITPSDIGLYGCWFSSQIYDEEATWELRVA
BTNL8 IgV SLRLENITVLDAGLYGCRISSQSYYQKAIWELQVS
****:***  * ***** :*** * ::* ***:*:
A B
C’ D
E F G
EC”
C
R
es
po
ns
e 
(R
U
)
0 5 10 15 20 25 30 35 40
B
200
150
100
50
R
es
po
ns
e 
(R
U
)
250
BTNL3KDQPFM IgV (μM)
0 10 20 30 5040 60
0
C
10
30
50
60
40
20
0
BTNL3RI IgV (μM)
R
es
po
ns
e 
(R
U
)
0 20 1008040 60
D
W
T 
K d
/m
ur
an
t K
d
1
0.1
E
BT
NL
3 I
gV
 W
T
BT
NL
3G
QF
SS  I
gV
BT
NL
3K
DQ
PF
M  Ig
V
BT
NL
3R
I  Ig
V
BT
NL
3Y
QK
AI  Ig
V
A 25
20
15
10
5
45
BTNL3GQFSS IgV (μM)
0.72
Bo
un
d/
Fr
ee
 (R
U
/μ
M
)
0.70
0.68
0.66
0.64
0.62
0.60
0.58
0.56
6 8 10 12 14 16 18 20 22 24
Bound (RU)
0.80
0.75
0.70
0.65
0.50
0.60
0.55
Bo
un
d/
Fr
ee
 (R
U
/μ
M
)
0 10 20 30 40 50 60
Bound (RU)
18
16
14
12
10
8
6
4
2
0
Bo
un
d/
Fr
ee
 (R
U
/μ
M
)
40 60 80 100 120 140 160 180 200 220 240
Bound (RU)
Figure 4. Regions of BTNL3 IgV Involved in Vg4 Binding
(A) Alignment of BTNL3 and BTNL8 IgV domains showing mutants generated.
(B–D) Equilibrium affinity analysis of the binding of (B) BTNL3GQFSS IgV (Kd = 117.6 mM), (C) BTNL3
KDQPFM mutant (Kd = 11.2 mM), or (D) BTNL3
RI mutant
(Kd = 217.3 mM) to Vg4 TCR.
(E) Binding affinity of indicatedmutants of BTNL3 (mutant Kd) relative toWT LES TCR affinity (WT Kd)measured in the same experiment. Data are representative of
two experiments.
(F) Flow cytometry analysis of 293T cells co-transduced with BTNL3 variants (as shown in the legend) and BTNL8 and stained with increasing concentrations
(x axis) of soluble Vg4Vd1 and anti-His mAb. Results are presented as geometric mean fluorescence intensity (gMFI) of staining with the sTCR plus antibody to the
His tag, normalized to the staining of 293T.EV cells under the same conditions.
See also Figure S4.
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Parallels between BTNL3 Recognition and BTN3A1-
Mediated P-Ag Sensing
To investigate whether the mode of ligand interaction employed
by Vg4 TCRs might have relevance for Vg9-mediated P-Ag
sensing, which is highly dependent upon the presence of
BTN3A1 on target cells, we used a hypothetical model (Melandri
et al., 2018) of the Vg4 TCR-BTNL3 interaction we had previously
generated with the computational docking program SwarmDock
to deduce three pairs of amino acids likely to contribute directly
to the interaction between Vg4 and BTNL3. Vg4-HV4 D, Y, and R
were predicted to contact BTNL3 H, W, and E, respectively (Fig-
ure 5A). We then identified counterpart amino acids in Vg9-HV4
(E, D, and H) by aligning with Vg4-HV4 (Figure 5B; Figure S5A)
and counterpart amino acids in BTN3A1-IgV (R, Y, and K) by
aligning with BTNL3-IgV (Figure 5C; Figure S5B).
Next, we generated two HV4g mutants, Vg9ED > KLVd2 and
Vg9H > RVd2, which were designed to introduce charge alter-
ations that might interfere with a putative analogous TCR-ligand
interaction. Both mutants displayed efficient cell surface expres-
sion in JRT3 cells, equivalent to the WT TCR from which they
were derived (Figure 5D), but abrogated CD69 upregulation in
response to zoledronate (Zol)-treated 293T cells (Figure 5E; Fig-
ure S5C). Hence, P-Ag sensing by the Vg9Vd2 TCR was critically
affected by specific HV4g residues in counterpart positions to
the Vg4 residues that mediate BTNL3 interactions.
We then tested whether P-Ag sensing might likewise be
affected by mutation of residues in the CFG face of the
BTN3A1 IgV domain (SSLRQ, YF, and YEKAL) corresponding
to those (NQFHA, WF, and DEEAT) implicated in the BTNL3
interaction with Vg4 HV4 (Melandri et al., 2018, and as described
earlier). Thus, we introduced non-conservative mutations of a
single amino acid in each BTN3A1 motif (SSLRQ > SSLEQ, YF
> DF, and YEKAL > YEMAL). When expressed in BTN3/
CRA123 cells (Vantourout et al., 2018), the 3A1SSLEQ and
3A1YEMALmutants each displayed cell surface expression similar
to that of WT BTN3A1 (Figure S5D), but compared with WT, they
both failed to support the potential of Zol-treated CRA123 cells
to stimulate two polyclonal Vg9Vd2 T cell lines (Figure 5F; Fig-
ure S5E). These findings clearly implicated the CFG face of
BTN3A1-IgV in the activation of P-Ag-reactive Vg9Vd2 T cells,
akin to the involvement of the counterpart regions of BTNL3 in
provoking human Vg4 responses (as described earlier). Note
that although the 3A1DF mutant also failed to support the poten-
tial of Zol-treated CRA123 cells to stimulate Vg9Vd2 cells, it
could not be excluded that this was because this construct
reached the cell surface inefficiently (Figure 5F; Figure S5D),
thereby implicating the YF motif in the stringent regulation of
BTN3A1 cell surface expression, as was previously considered
(Vantourout et al., 2018).
Although BTN3A1 can be sufficient to support P-Ag stimula-
tion of Vg9Vd2 T cells, this is greatly increased by co-expression
of BTN3A2, which regulates the trafficking and cell surface
expression of BTN3A1 via heteromerization (Vantourout et al.,
2018). We therefore investigated whether the CFG face muta-
tions of BTN3A1 could be complemented by WT BTN3A2, and
vice versa. Thus, we generated the same CFG motif mutants of
BTN3A2 and tested the expression of each combination (i.e.,
3A1mutant + 3A2wt, 3A1wt + 3A2mutant, and 3A1mutant + 3A2mutant)
in CRA123 cells. Again, the SSLEQ and YEMAL mutants dis-820 Immunity 51, 813–825, November 19, 2019played cell surface expression similar to WT BTN3A1+BTN3A2,
while the DFmutants showed decreased expression, particularly
when both BTN3A1 and BTN3A2 carried this mutation (Fig-
ure S5F). However, when co-expressed with BTN3A2, the CFG
face mutations in BTN3A1 negligibly affected Zol-induced
CD107a upregulation by polyclonal Vg9Vd2 T cells (Figure 5G).
By contrast, CFG face mutations in BTN3A2 could not be
rescued by co-expression of WT BTN3A1, impairing CD69 upre-
gulation almost as much as when BTN3A1 and BTN3A2 were
both mutated in the CFG faces (Figure 5G; Figure S5G). More-
over, similar impacts were observed when the responders
were JRT3 cells expressing a WT Vg9Vd2 TCR (Figures S5H
and S5I). Altogether, these data show that three systems of
BTN-mediated gd T cell regulation—human Vg4 and BTNL3.8,
murine Vg7 and Btnl1.6, and human Vg9 and BTN3A—receive
critical contributions from HV4 of the relevant TCR Vg chain
and from specific, orthologous IgV-CFG face residues of the
relevant BTNs.
DISCUSSION
Over the past decade, it has become clear that BTN and BTNL/
Btnl members of the B7 superfamily play critical roles in gd T cell
selection and activation in mice and humans, spanning both
peripheral blood and tissue-associated subsets (Barbee et al.,
2011; Boyden et al., 2008; Di Marco Barros et al., 2016; Harly
et al., 2012; Turchinovich and Hayday, 2011). Nonetheless,
although several studies have shed light on the mechanism(s)
underpinning this profound biology, key aspects have remained
largely unresolved, in particular whether there are direct interac-
tions of the relevant TCRs with BTN, BTNL, or Btnl proteins.
Addressing this, the current study provides unequivocal evi-
dence that the human BTNL3.8 heterodimer interacts directly
with Vg4 gd TCRs, specifically via the BTNL3 chain. This builds
on previous work demonstrating that cells expressing BTNL3.8
complexes could induce TCR-mediated stimulation of human
Vg4 gut T cells, while the counterpart murine molecules,
Btnl1.6, induced TCR triggering of mouse gut Vg7 T cells
(Di Marco Barros et al., 2016; Melandri et al., 2018).
Previously, the only evidence of BTN or BTNL directly
engaging the TCR was provided by Vavassori et al. (2013),
who reported direct binding of a Vg9Vd2 TCR to the BTN3A1
ectodomain, which was also reported to present P-Ag. However,
both findings have been convincingly challenged (Sandstrom
et al., 2014), and our laboratory has similarly failed to reproduce
Vg9Vd2 TCR-BTN3A1 binding. In contrast to this, the current
study, which incorporates evidence from a combination of
SPR, ITC, and mutagenesis, not only documents direct binding
of the BTNL3 IgV domain to Vg4 but also demonstrates an inter-
action modality resembling that of superantigens (Sundberg
et al., 2007) in its complete dependence on germline-encoded
Vg4 HV4 and its substantial reliance on germline-encoded
Vg4 CDR2.
Although our study focused predominantly on the LES clono-
type as a model Vg4 TCR, the binding modality we outline fully
explains both the specificity of BTNL3 binding to Vg4 TCRs,
but not to Vg2 or Vg3 TCRs, and our previous findings that
BTNL3.8 dimers trigger TCR downregulation of essentially
any TCRs that are Vg4+, irrespective of CDR3g or TCR Vd
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Figure 5. The HV4 Region of the Vg9 TCR and the CFG Face of BTN3A1 and BTN3A2 Are Involved in the Phosphoantigen-Induced Activation
of Vg9Vd2 T Cells
(A) Best fit hypothetical model for docking of the Vg4 TCR V domain (light gray) onto the BTNL3 IgV domain (green) (Melandri et al., 2018), generated using the
computational docking program SwarmDock. Side chains are displayed for amino acids potentially directly involved in the contact between the Vg4 HV4 region
(D, Y, and R; pink) and the CFG face of the BTNL3-IgV domain (H61, W115, and E124; orange, blue, and red, respectively).
(B and C) Alignment of the HV4 region of the Vg4 and Vg9 TCR V domains (B) and the IgV domains of BTNL3 and BTN3A1 and BTN3A2 (C). Amino acids of interest
are colored as in (A).
(D) Flow cytometry analysis of the expression of the indicated Vg9Vd2 TCR variants by JRT3 cells, 72 h post-transduction.
(E) Flow cytometry analysis of CD69 upregulation by JRT3 cells expressing the indicated Vg9Vd2 TCR variants, following incubationwith media only, or 293T cells
with or without pre-treatment with zoledronate (Zol, 10 mM). Data are representative of three experiments (mean ± SD of n = 3 co-cultures).
(F) Flow cytometry analysis of CD107a upregulation by polyclonal Vg9Vd2 T cell lines derived from peripheral blood mononuclear cells from two donors following
co-culture with CRA123 cells transfected with the indicated BTN3A1 constructs (EV, empty vector control) and pre-treated with 10 mM Zol. Data are the mean ±
SD of n = 3 co-cultures for each donor.
(G) Flow cytometry analysis of CD107a upregulation by a polyclonal Vg9Vd2 T cell line following co-culture with CRA123 cells co-transfected with the indicated
BTN3A1 + BTN3A2 constructs (EV, empty vector control) and pre-treated with 10 mM Zol. Data are the mean ± SD of n = 3 co-cultures.
See also Figure S5.
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usage (Melandri et al., 2018). In this respect, it is challenging to
understand the claim that a Vg4+ TCR identified in a celiac dis-
ease gut failed to respond to BTNL3-expressing cells (Mayassi
et al., 2019). Indeed, by using a cellular assay of TCR and CD3
downregulation, we show here that manipulating the length and
sequence of the Vd1-CDR3 region had negligible, if any, effects
on the efficiency of BTNL3.8 recognition, even when long
CDR3 regions were incorporated. Despite this, some modest
differences in CD69 upregulation were observed. The failure
of Mayassi et al. (2019) to detect a BTNL3-mediated response
of a particular Vg4+ TCR might reflect their use of a less sensi-
tive assay system. This notwithstanding, we cannot formally
exclude that rare CDR3d regions might indirectly affect the
interaction, for example, via effects on CDR2 loop conforma-
tion. Indeed, we note that different TCRs can transduce
quantitatively different signals in response to anti-CD3 agonist
antibodies (Melandri et al., 2018), which must also reflect
indirect effects.
Considering that BTNL3.8 and Btnl1.6 heteromers are
expressed specifically by intestinal epithelial cells of humans
and mice, respectively, extrapolation of the findings presented
here to Btnl6-mediated interactions with Vg7 would readily
explain how BTNL/Btnl proteins can act as tissue-specific,
non-clonal selecting elements for signature gd T cell compart-
ments defined by discrete Vg chains. Our demonstration in the
current study that mouse Vg7 multimers specifically stain
Btnl1.6-expressing target cells, combined with mutagenesis
studies, is consistent with the evolutionary conservation of the
mode of action to BTNL3.8.
By focusing on the LES Vg4 TCR that we have previously
shown to recognize EPCR (Willcox et al., 2012), we were able
to compare TCR recognition of BTNL3 with that of a clonally
restricted antigenic ligand. The private LES clonotype expanded
substantially in an individual after CMV infection, adopted an
effector phenotype (Lafarge et al., 2005), and appeared to align
closely with the adaptive biology that has recently emerged for
some human gd T cell subsets, including Vd2neg and Vg9negVd2+
T cells, which can both demonstrate highly focused clonotypic
expansion and differentiation after antigenic challenge (Davey
et al., 2018a). Our study provides unequivocal data that BTNL3
engages the TCR by a qualitatively different modality to that by
which clonally restricted ligands engage the TCR. Whereas the
former (BTNL3)modality focused predominantly on germline-en-
coded regions (the HV4 and CDR2 regions were sufficient to
confer essentially complete BTNL3.8 recognition upon human
Vg3 and upon a heterologous mouse Vg7 TCR), the latter
(EPCR) modality was energetically focused on CDR3g and
CDR3d regions that are generated by somatic gene rearrange-
ment. Although this latter CDR3 mode might be expected to
incur substantial entropic penalties upon binding, as for both
CDR3-driven antibody-antigen and ab TCR-peptide-major his-
tocompatibility complex (MHC) binding (Stites, 1997; Willcox
et al., 1999), a notable feature of Vg4+ TCR-BTNL3 interaction
evident from our ITC data was a relatively modest change in en-
tropy, suggestive of a more rigid body interaction mode. This is
consistent with our hypothetical model of Vg4+ TCR-BTNL3
interaction (Melandri et al., 2018), whereby theHV4 andCDR2 el-
ements involved in the Vg4+ TCR derive from b sheet structure,
which might remain relatively rigid even in the unbound state.822 Immunity 51, 813–825, November 19, 2019Future studies will be needed to understand whether this is a
common feature of TCR-BTN, TCR-BTNL, and mouse TCR-
Btnl protein interactions.
The full scope of these two ligand interaction modalities is
currently unclear. Possibly, one modality is exclusive of the
other; consistent with this, our results indicate the LES TCR
is unable to engage both BTNL3 and EPCR synchronously.
This argues strongly against any universal requirement for co-
engagement of BTNL3 and antigenic ligands in TCR-mediated
stimulation of Vg4+ T cells. Consistent with this, in some
donors, clonally expanded Vg4Vd1+ and Vg4Vd2+ adaptive-
like populations can be identified in both peripheral blood
and liver where BTNL3.8 is not expressed (Davey et al., 2017;
Hunter et al., 2018; Di Marco Barros et al., 2016). However, it
remains possible that there is sequential use of the two modal-
ities: thus, selection and/or tonic engagement of BTNL3.8 may
be an essential preface to clonotypic antigen engagement
within the Vg4+ T cell compartment in response to various
forms of tissue dysregulation.
Alternatively, it cannot be discounted that one gd T cell might
only ever respond via one of the two modalities. By this means,
gd T cells would collectively provide complementary, innate-like,
and adaptive arms to the gd T cell response. Studies on adaptive
gd T cells have highlighted their potential, following antigenic
challenge, to populate tissues with clonally expanded subsets
that have heightened effector capability and are likely to provide
ongoing immune surveillance against recurrently encountered
challenges (Hunter et al., 2018). However, such responses are
likely to be highly dependent upon exposure to specific immuno-
logical scenarios such as pathogen infection, including CMV
(Davey et al., 2017, 2018b; Ravens et al., 2017), or possibly anti-
genic changes underlying autoimmune or inflammatory
conditions.
In contrast, the constitutive, selective tissue associations of
BTNL/Btnl molecules have the potential to pre-populate relevant
tissues with functionally distinct innate-like gd T cells (Boyden
et al., 2008; Di Marco Barros et al., 2016; Turchinovich and Hay-
day, 2011). Given that the respective TCR binding modalities we
observe might permit gd T cells collectively to make either
innate-like or adaptive responses, it will be important to study
whether the two modalities induce distinct TCR-mediated
signaling pathways, as seems to be the case for ab TCR-activat-
ing superantigens that engage HV4 regions of TCR Vb versus
peptide-MHC engagement that depends on the CDR3 regions
(Bueno et al., 2006). Studies on intraepithelial gd T cell popula-
tions have suggested that these cells can make growth factors
such as keratinocyte growth factor, insulin-like growth factor,
and amphiregulin, consistent with roles in epithelial homeostasis
(Boismenu and Havran, 1994; Krishnan et al., 2018; Mayassi
et al., 2019; Shires et al., 2001). Conceivably, engagement of
BTNL/Btnl family members (or related Skint molecules in the
skin) might stimulate the cells’ production of growth factors
involved in tissue repair and homeostasis, while engagement
of clonally restricted antigen might induce different functional
outcomes, such as the production of interferon (IFN) g, or inter-
leukin-13 (IL-13) (Dalessandri et al., 2016). In this regard, the ce-
liac gut was reported to harbor an enrichment of more adaptive,
clonally expanded Vg4 gd T cells, which were hypothesized to
contribute to inflammation (Mayassi et al., 2019).
Future studies should explore the generality of bimodal anti-
gen receptor binding. Several sets of data, including some pre-
sented here, strongly argue that this will be conserved for murine
intestinal intraepithelial Vg7 cells, which are strictly regulated by
Btnl1.6 heteromer but may display CDR3-mediated clonal or
oligoclonal responses to other antigens, including T10 and T22
(Shin et al., 2005). In particular, our observation that Vg7 TCR-
Btnl1.6 recognition is abolished either by substituting mouse
Vg7 CDR2 and HV4 regions with those of human Vg4 or by
mutating Btnl6 residues at positions equivalent to BTNL3
residues implicated in Vg4 TCR binding strongly suggests a
Vg7-Btnl6 recognition mode analogous to Vg4-BTNL3.
Likewise, although BTN3A1-dependent P-Ag responses of
human peripheral blood Vg9Vd2 cells are irrefutably associated
with specific TCRg junction (Jg) region sequences (Bukowski
et al., 1998; Delfau et al., 1992), in the manner of adaptive reac-
tivities, the rapid and universal response of Vg9Vd2 cells to
P-Ags (Davey et al., 2018b; Morita et al., 1995) appears to be
innate-like. Despite the highly distinct biology of Vg9Vd2 lympho-
cytes relative to intestinal Vg4+ and Vg7+ T cells, it is striking that
their BTN3A-dependent response to P-Ags was eliminated by
Vg9 HV4 mutations in counterpart positions to Vg4 HV4 muta-
tions that abrogate BTNL3 binding and that BTN3A-CFG muta-
tions analogous to BTNL3 regions involved in binding Vg4
severely diminished P-Ag sensing. In addition, the strong impact
of mutations in BTN3A2 relative to BTN3A1 was highly intriguing,
particularly given their identical IgV domain sequence. Clearly,
additional work is needed to clarify the precise molecular targets
recognized by the Vg9Vd2 TCR and the modalities by which they
are engaged. Data presented here further implicate the V region
of BTN3A2 in Vg9Vd2 T cell responses, which likewise merits
follow-up. Importantly, in light of the failure to detect direct bind-
ing of Vg9Vd2 TCR to BTN3A1, our mutational data might imply
that BTN3A1 or BTN3A2 does indeed interact with the Vg9Vd2
TCR but either does so weakly and/or in concert with additional
moieties, candidates for which might include the F1-ATPase
(Scotet et al., 2005). Supporting the feasibility of this suggestion,
a recent crystallographic study of pollen allergen-antibody
recognition highlighted simultaneous interaction of each Fab
fragment with two separate ligand surfaces: one via a superanti-
gen-like modality involving germline-encoded receptor regions
and the other involving a more conventional CDR3-mediated
interaction (Mitropoulou et al., 2018).
In the most extreme generality, the existence of distinct, par-
allel ligand recognitionmodesmight be a feature ofmany antigen
receptors. Thus, there are ab TCRs that can engage endogenous
or exogenous superantigens via germline-encoded subdomains
and peptide-MHC complexes largely via recombination-depen-
dent CDR3 subregions (Sundberg et al., 2007). Moreover, there
is increasing interest in antibodies that disproportionately
employ HV4 in antigen binding (Meyer et al., 2016). In this regard,
our present and prior studies argue strongly that the gd TCR re-
tains the potential for bimodal ligand recognition. Moreover, this
appears to be an evolutionarily conserved trait, at least from
mice to humans, with many properties of mouse Vg7 being
shared with human Vg4. Given that distinct tissue associations
based on Vg region usage are a signature of several gd T cell
populations in mice, it may be that other B7-like ligands operate
at defined anatomical sites to engage the HV4 andCDR2 regionsof the relevant murine TCR Vg regions, thereby regulating
unique, tissue-specific subsets of gd T cells. In this regard, the
emerging alignment betweenmouse and human gd T cell biology
in TCR-mediated recognition of BTNL molecules fuels optimism
that further studies on mouse gd TCR ligands may greatly inform
human gd T cell biology and its relationship tomyriad pathophys-
iologies. Furthermore, given that HV4 and CDR2 are germline-
encoded, their interactions with ligands may have contributed
to the inheritance patterns of particular V gene segments across
Ig, ab TCRs, and gd TCRs.
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BTNL8 IgV This paper N/A
Soluble T cell receptors (sTCRs) Willcox et al., 2012 and this paper N/A
Soluble EPCR Willcox et al., 2012 and this paper N/A
Experimental Models: Cell Lines
J76 (human) Francis Crick Institute (FCI) Cell Services N/A
MODE-K (mouse) Gift from Dr. D. Kaiserlian,
INSERM U1111, Lyon, France
N/A
(Continued on next page)
e1 Immunity 51, 813–825.e1–e4, November 19, 2019
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
JRT3 (human) Gift from Dr. S. Mansour, University
of Southampton
N/A
293T (human) ATCC N/A
293T BTNL variants and EV cell lines Di Marco Barros et al., 2016;
Vantourout et al., 2018;
Melandri et al., 2018
N/A
MODE-K Btnl variants and EV cell lines Di Marco Barros et al., 2016;
Melandri et al., 2018
N/A
293T CRA123 (BTN3 locus deletion) Vantourout et al., 2018 N/A
J76/JRT3 TCR variants This paper and Melandri et al., 2018 N/A
Oligonucleotides
Full length cloning primers for
BTN3, Btnl, BTNL
Di Marco Barros et al., 2016;
Vantourout et al., 2018;
Melandri et al., 2018;
N/A
Recombinant DNA
pCSIGPW, pCSIYHW Di Marco Barros et al., 2016 N/A
pCR/V1 Zennou et al., 2004 N/A
pHIT/G Fouchier et al., 1997 N/A
pET23a Merck Millipore Cat#69745-3
pMT/BiP/V5-HisB Invitrogen Cat#V413020
FLAG-Btnl1 in pCSIYHW Di Marco Barros et al., 2016 N/A
HA-Btnl6 in pCSIGPW Di Marco Barros et al., 2016 N/A
Human and mouse gdTCRs in pCSIGW This paper and Melandri et al., 2018 N/A
FLAG-BTNL3 in pCSIGPW This paper and Melandri et al., 2018 N/A
HA-BTNL3 in pCSIGPW This paper and Melandri et al., 2018 N/A
FLAG-BTN3A1 in pCSIGPW This paper and Vantourout et al., 2018 N/A
HA-BTN3A2 in pCSIGPW This paper and Vantourout et al., 2018 N/A
BTNL3 IgV in pET23a (wild type and mutants) This paper N/A
BTNL8 IgV in pET23a This paper N/A
Human and mouse gdTCRs in
pMT/BiP/V5-HisB
This paper and Willcox et al., 2012 N/A
EPCR in pMT/BiP/V5-HisB Willcox et al., 2012 N/A
Software and Algorithms
FlowJo version 10 FlowJo LLC https://www.flowjo.com/
PyMOL version 2.0.7 Schrodinger LLC https://pymol.org
GraphPad Prism versione 8.0.2 GraphPad Software LLC https://www.graphpad.com
BIAevaluation GE Healthcare https://www.gelifesciences.com/en/gb/shop/
protein-analysis/spr-label-free-analysis
Origin 2015 OriginLab https://www.originlab.com/
Other
Sensor Chip CM5 GE Healthcare 29149604
Sensor Chip NTA GE Healthcare BR100407
HBS-P GE Healthcare BR100368
HBS-EP GE Healthcare BR100188
Streptavidin Sigma S4622LEAD CONTACT AND MATERIALS AVAILABILITY
For additional information about reagents and resources, contact the lead contact, Benjamin E. Willcox, at b.willcox@bham.ac.uk.Immunity 51, 813–825.e1–e4, November 19, 2019 e2
METHOD DETAILS
Soluble Protein Production
cDNA encoding wt BTNL3 or BTNL8 IgV domains (Q18 to V131), or BTNL3 IgV incorporating the described mutations, were gener-
ated as gblocks (Integrated DNA Technologies) including the sequence for a C-terminal 6x Histidine tag, cloned into the pET23a
expression vector (Novagen), andwere overexpressed in E. coliBL21 (DE3) strain (NEB). Protein expression was induced by addition
of 0.5mM isopropyl-b-D-1-thiogalactopyranoside and culture for 4 hours at 37C. The bacterial cell pellet was harvested by centri-
fugation at 7500 g for 20 min, resuspended in PBS and lysed by mechanical disruption using an Emulsiflex C3. The overexpressed
inclusion body protein was isolated by centrifugation at 44000 g for 30 min. The pellet was washed three times in 50mM Tris, pH8,
0.5% Triton X-100, 2 mMDTT, and 0.1% sodium azide, and once in 50 mM Tris, pH8, 2 mMDTT, and 0.1% sodium azide, then solu-
bilised in 8 M urea, 50 mMMES, pH 6.5, 1 mM EDTA, 2 mM DTT. BTNL3 or BTNL8 inclusion body proteins were further reduced by
addition of fresh 20 mM DTT for 30 min at 37C immediately prior to refolding. BTNL3 IgV was refolded by dilution in 100 mM Tris,
400mM L-Arginine-HCl, 2 mMEDTA, 6.8 mM cystamine, 2.7 mM cysteamine, 0.1 mMPMSF, pH 8, overnight at 4C. BTNL8 IgV was
refolded as described for Skint1 IgV (Salim et al., 2016). The refolding mixture was concentrated down and purified by size exclusion
chromatography on a Superdex-200 column (GE Healthcare) pre-equilibrated with 20 mM Tris, 150 mM NaCl, pH 8, or PBS. Soluble
gd TCRs (LES TCR (Vg4+; wt and mutants), Vg2+ TCR, Vg3+ TCR and mouse Vg7+ TCR) and soluble EPCR were generated in
Drosophila S2 cells and purified by nickel chromatography as previously described (Willcox et al., 2012). Mutant Vg4 and Vd5 con-
structs were generated using theQuickchange site-directedmutagenesis kit (Stratagene) of wt LES TCR constructs in pMT/BiP/HisB
(Invitrogen) (Willcox et al., 2012). TCRs were then biotinylated via a C-terminal BirA tag. Soluble Vg4Vd1 TCRs used to stain
293T.L3L8 cells were described previously (Melandri et al., 2018).
Surface Plasmon Resonance
SPR was performed as described (Willcox et al., 1999) on a BIAcore3000 using streptavidin-coated CM5 chips and HBS-EP buffer
(GE Healthcare). Biotinylated wt or mutant LES TCR and control Vg2 or Vg3 TCRs (1000-3500 RU), were captured on the Streptavidin
chip. Analyte concentrations ranged from 1-200 mM. The BTNL3-EPCR competition assay was performed by immobilising 2500-
3000 RU of wt EPCR or control protein (EPCR R127A mutant, which abrogated binding to LES TCR), (Willcox et al., 2012) on the
surface of the chip. Injections of LES TCR at a constant concentration of 12.5 mM were performed in the presence of increasing
concentrations of BTNL3 IgV (3.5-113 mM), or BTNL8 IgV (2.2-70.5 mM). Binding of BTNL3 polyclonal antibody was measured
following immobilisation of His-tagged BTNL3 IgV mutants to an NTA Sensor Chip in HBS-P (GE Healthcare).
Isothermal Titration Calorimetry
Calorimetric measurements were carried out using an iTC200 instrument (Malvern Panalytical, Malvern, UK). All experiments were
performed at 20C, with proteins purified in 20mM Tris pH 8, 50 mM NaCl. Typically, TCR proteins were contained in the calorimeter
cell at a concentration of 70 mM, into which BTNL3 proteins at a ten-fold higher molar concentration were titrated as 20 3 2 ml
injections. All ITC binding experiments were corrected for heats of dilution. Binding data were analyzed by fitting the binding isotherm
to a single independent binding site model using Origin software.
Cell Lines
293T and MODE-K cells were maintained in DMEM supplemented with 4.5 g/L D-glucose, L-glutamine, 10% heat-inactivated fetal
calf serum (FCS) and 1% penicillin-streptomycin (Complete DMEM). JRT3 and Jurkat 76 (J76) were maintained in RPMI 1640 with L-
glutamine, 10% heat-inactivated FCS and 1% penicillin-streptomycin (Complete RPMI). All cell culture reagents were from Thermo
Fisher. Polyclonal Vg9Vd2 T cell lines were generated from PBMC from healthy donors after informed consent as described previ-
ously (Vantourout et al., 2018).
Reagents
Transduced 293T and MODE-K cells were grown in Complete DMEM supplemented with 1 mg/mL puromycin (Sigma-Aldrich) alone
or in combination with 500 ng/mL hygromycin B (Thermo Fisher). Polyethylenimine was from Polysciences. Zoledronate (Zol) was
from Sigma-Aldrich.
Mutagenesis and Molecular Biology
Plasmids encoding hu17 (human Vg4Vd1), huPB (human Vg9Vd2) andmo5 (murine Vg7Vd2-2) TCRs, andBTNL andBtnl variants, and
BTN3A1 and BTN3A2 have been described (Melandri et al., 2018; Vantourout et al., 2018). Chimeric and mutant TCRs were gener-
ated using overlap-extension PCR (OE-PCR) and cloned into the self-inactivating lentiviral vector pCSIGPW after removal of the
IRES-GFP and CMVp-PuroR cassettes. OE-PCR was likewise used to mutate BTN3A1 and BTN3A2, which were subsequently
cloned into pCSIGPW.
Lentiviral Transduction
Lentiviral particles were produced in wild-type 293T cells by co-transfection with lentiviral plasmids encoding target proteins (derived
from pCSIGPW), HIV-1 gag-pol pCR/V1 (Zennou et al., 2004) and VSV-G env pHIT/G (Fouchier et al., 1997) using PEI. Medium wase3 Immunity 51, 813–825.e1–e4, November 19, 2019
replaced after 16 h and collected 48 h post-transfection, filtered through 0.45 mmnylon mesh, and used to transduce target cell lines.
JRT3/J76 cells were transduced by spinoculation at 1,000 g, 20C for 30 min. 5x105 293T cells/well were plated in a 12-well plate a
day prior to transduction. The following day, supernatants from the packaging cell lines weremixed 1:1 and 1.5mLwas used to trans-
duce plated 293T cells. Culture mediumwas supplemented with antibiotics for selection 24 h post-transduction. Transductants were
bulk-sorted on uniform GFP expression.
Co-culture Assay
0.5 3 105 JRT3/J76 transductants or PBMC-derived polyclonal Vg9Vd2 T cells were mixed in 96-well plates with 1.5 3 105 293T or
MODE-K cells, followed by co-culture for 5 h. 293T transiently expressing BTNL3 and BTNL8 (293T.L3L8) were used in blocking
experiments. 48 h post-transfection, 293T cells were harvested and pre-incubated for 30min at 4Cwith a-FLAG, a-HA or IgG control
antibodies (L5, 16B12, MG1-45 respectively; BioLegend). JRT3 were subsequently added and the cells were co-cultured for 3h at
37C in the presence of the antibodies. For blocking experiments of murine Btnl molecules, MODE-K stably expressing Btnl1+Btnl6
(MODE-K.l1.l6) were pre-incubated for 60 min at 37C with a-FLAG, a-HA or IgG control antibodies in 96-well plates. J76-mo5 were
added to the wells and cells were co-cultured for 5h in the presence of the antibodies. 293T-CRA123 cells were transiently trans-
fectedwith BTN3 constructs. Media was replaced 24 h post-transfection with Complete DMEM supplemented with Zol (10 mM). Cells
weremaintained for 16 h, washed twice, and co-cultured with JRT3 transductants or PBMC-derived polyclonal Vg9Vd2 T cell lines as
described above.
Flow Cytometry
Flow cytometry was performed using the following antibodies from BioLegend, unless otherwise stated. Antibodies to the following
human molecules were used: CD69-AF647 (FN50), CD69-PE (FN50), CD3-BV421 (OKT3), gdTCR-PeCy7 (IMMU510; Beckman
Coulter), CD45-PacificBlue (HI30), TCRVd2-FITC (B6). Antibodies to the following murine molecules were used: TCRd-PerCPe710
(GL3), TCRd-APC (GL3), Vg7-AF647 (F2.67, provided by P.Pereira). Other antibodies were as follows: DYKDDDDK-PE (FLAG, L5),
HA-AF647 (16B12). 6xHis-APC (Biolegend, J095G46). Data were acquired on BD Canto II or Fortessa cytometers. sTCR staining
was performed as in Melandri et al. (2018).
Software
Flow cytometry data were analyzed in FlowJo (versions 9 and 10; FlowJo, LLC) and Prism (version 7; GraphPad). Structural figures
were generated in PyMOL (version 2.0.7; Schrodinger, LLC). For SPR and ITC, data were analyzed in BIAevaluation (GE Healthcare)
and Origin 2015 (OriginLab).
Molecular Modeling
Molecular models of the BTNL-3 and BTNL-8 IgV-IgC domains were derived from the I-TASSER server (Yang et al., 2015). BTNL-3
and BTNL-8 IgV-IgC domain models were then superimposed onto the equivalent regions of previously published BTN3A1 structure
adopting either the V-shaped or head-to-tail dimer (Palakodeti et al., 2012). Residues that contribute to stabilizing BTN3A1 and
BTNL-3/BTNL-8 dimer interfaces were identified using programs of the CCP4 suite (Winn et al., 2011).
QUANTIFICATION AND STATISTICAL ANALYSIS
Flow cytometry data were analysed in FlowJo (versions 9 and 10; FlowJo) and Prism (version 7; GraphPad). Structural figures were
generated in PyMOL (version 2.0.7; Schrodinger). For SPR and ITC, data were analysed in BIAevaluation (GE Healthcare) and Origin
2015 (OriginLab).
DATA AND CODE AVAILABILITY
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